Addex spin-out Neurosterix completes Phase 1 trials of NTX-253 in schizophrenia, targets Phase 2

(AWP Alliance News) - Addex Therapeutics said its spin-out Neurosterix completed Phase 1 studies of NTX-253, clearing the program to move into Phase 2 development for schizophrenia. Results have already been generated from the Phase 1 work, with the studies providing supportive safety and pharmacokinetic findings without disclosing detailed performance metrics.

Neurosterix plans to start Phase 2 testing in patients, a step that could increase the asset's strategic value if early clinical signals hold up. Addex holds a 20% equity stake in Neurosterix, which was formed in April 2024 with USD 65 million raised in a Series A financing.

https://www.globenewswire.com/NewsRoom/ReleaseNg/402524168

Disclaimer: This news brief was created using generative artificial intelligence. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire on October 08, 2026, and is solely responsible for the information contained therein.